Ocular translational science: A review of development steps and paths

Abstract Developing successful drug delivery methods is challenging for any tissue, and the eye is no exception. Translating initial concepts into advanced technologies treating diseases in preclinical models and finally into functional and marketable products for humans can be particularly daunting. While referring to specific ophthalmic companies and products, this review considers key exchanges that lead to successful translation. By building on basic science discoveries in the academic setting, applied science can perform proof‐of‐concept work with simple, benchtop experiments. Eventually, simple models need to be translated to more robust ones where cells, tissues, and entire organisms are incorporated. Successful translation also includes performing due diligence of the intellectual property, understanding the market needs, undertaking clinical development, meeting regulatory requirements, and eventually scale up manufacturing. Different stages of the translation can occur in different environments, including moving from academia to industry, from one company to another, or between veterinary and human applications. The translation process may also rely on contract organizations to move through the complex landscape. While the path to a commercial, marketable product may not look the same each time, it is important to design a development plan with clear goals and milestones to keep on track. Graphical abstract Figure. No Caption available.

[1]  D. Gould Feline Herpesvirus-1 , 2011, Journal of feline medicine and surgery.

[2]  R. S. Viola,et al.  Collagen shields as a vehicle for collecting and studying migratory cells on human corneas. , 1992, Investigative ophthalmology & visual science.

[3]  J M J Roodhooft,et al.  Leading causes of blindness worldwide. , 2002, Bulletin de la Societe belge d'ophtalmologie.

[4]  R. Lau,et al.  Azithromycin and Doxycycline Attenuation of Acanthamoeba Virulence in a Human Corneal Tissue Model , 2016, The Journal of infectious diseases.

[5]  S. Graham,et al.  Onchocerca ochengi infections in cattle as a model for human onchocerciasis: recent developments , 2000, Parasitology.

[6]  Ivana K. Kim,et al.  Diffusion of high molecular weight compounds through sclera. , 2000, Investigative ophthalmology & visual science.

[7]  J. Parel,et al.  Reduction of corneal edema in endotoxin-induced uveitis after application of L-NAME as nitric oxide synthase inhibitor in rats by iontophoresis. , 1998, Investigative ophthalmology & visual science.

[8]  Hongming Chen,et al.  Topical Ocular Drug Delivery to the Back of the Eye by Mucus-Penetrating Particles. , 2015, Translational vision science & technology.

[9]  Ulrich Dirnagl,et al.  Changing the Mindset in Life Sciences Toward Translation: A Consensus , 2014, Science Translational Medicine.

[10]  J. Mould,et al.  Canine keratoconjunctivitis sicca: disease trends in a review of 229 cases. , 2007, The Journal of small animal practice.

[11]  C. L. Schlamp,et al.  Mouse models of retinal ganglion cell death and glaucoma. , 2009, Experimental eye research.

[12]  T. Desai,et al.  Biocompatibility and Pharmacokinetic Analysis of an Intracameral Polycaprolactone Drug Delivery Implant for Glaucoma , 2016, Investigative ophthalmology & visual science.

[13]  S. Masket,et al.  Sustained‐release dexamethasone for the treatment of ocular inflammation and pain after cataract surgery , 2015, Journal of cataract and refractive surgery.

[14]  M. Blumenkranz,et al.  Selection of therapeutic agents for intraocular proliferative disease. Cell culture evaluation. , 1984, Archives of ophthalmology.

[15]  C. Mellersh,et al.  Mutation in HSF4 is associated with hereditary cataract in the Australian Shepherd. , 2009, Veterinary ophthalmology.

[16]  H. Mcdevitt,et al.  Endotoxin-induced uveitis in rats as a model for human disease , 1980, Nature.

[17]  J. Hovanesian,et al.  Efficacy and Safety of Sustained Release Dexamethasone for the Treatment of Ocular Pain and Inflammation after Cataract Surgery: Results from Two Phase 3 Studies , 2016 .

[18]  K N Gelatt,et al.  Animal models for glaucoma. , 1977, Investigative ophthalmology & visual science.

[19]  Naseem A. Charoo,et al.  Ophthalmic Delivery of Ciprofloxacin Hydrochloride from Different Polymer Formulations: In Vitro and In Vivo Studies , 2003, Drug development and industrial pharmacy.

[20]  Y. Pathak,et al.  Ocular Drug Delivery: Impact of In Vitro Cell Culture Models , 2016 .

[21]  G. Box Robustness in the Strategy of Scientific Model Building. , 1979 .

[22]  J. Fischbarg,et al.  The Role of the Tight Junction in Paracellular Fluid Transport across Corneal Endothelium. Electro-osmosis as a Driving Force , 2006, The Journal of Membrane Biology.

[23]  S. P. Srinivas In situ measurement of fluorescein release by collagen shields in human eyes. , 1994, Current eye research.

[24]  C. Foster,et al.  Gross Factors in Treatment of Nonhealing Corneal Ulcers and Recurrent Erosions , 1989, Cornea.

[25]  H. Kaufman,et al.  Clinical uses of collagen shields , 1988, Journal of cataract and refractive surgery.

[26]  J. Aquavella,et al.  Effect of a collagen shield on cat corneal epithelial wound healing. , 1989, Investigative ophthalmology & visual science.

[27]  D. Williams Immunopathogenesis of keratoconjunctivitis sicca in the dog. , 2008, The Veterinary clinics of North America. Small animal practice.

[28]  M. Almukainzi,et al.  Simulated Biological Fluids with Possible Application in Dissolution Testing , 2011 .

[29]  M. Heath,et al.  Prevalence of canine cataract: preliminary results of a cross-sectional study. , 2004, Veterinary ophthalmology.

[30]  G. Prestwich,et al.  A cross-linked hyaluronan gel accelerates healing of corneal epithelial abrasion and alkali burn injuries in rabbits. , 2010, Veterinary ophthalmology.

[31]  M. Taravella,et al.  Collagen shield delivery of ofloxacin to the human eye. , 1999, Journal of cataract and refractive surgery.

[32]  O de Silva,et al.  The HET-CAM, a Useful In Vitro Assay for Assessing the Eye Irritation Properties of Cosmetic Formulations and Ingredients. , 1999, Toxicology in vitro : an international journal published in association with BIBRA.

[33]  David L. Williams The Rabbit Eye , 2013 .

[34]  Yubing Xie,et al.  Recreating a human trabecular meshwork outflow system on microfabricated porous structures , 2013, Biotechnology and bioengineering.

[35]  M. Byrne,et al.  In vitro controlled release of an anti-inflammatory from daily disposable therapeutic contact lenses under physiological ocular tear flow. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[36]  J. Parel,et al.  Iontophoresis of dexamethasone in the treatment of endotoxin-induced-uveitis in rats. , 1997, Experimental eye research.

[37]  J. Parel,et al.  Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels. , 2002, Experimental eye research.

[38]  E. Toropainen,et al.  Cell culture models of the ocular barriers. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[39]  S. Scoper Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy , 2008, Advances in therapy.

[40]  R. Beuerman,et al.  The effect of collagen shields on epithelial wound healing in rabbits. , 1989, American journal of ophthalmology.

[41]  Adrian P. Rowley,et al.  Finite element modeling of retinal prosthesis mechanics , 2009, Journal of neural engineering.

[42]  S. Schwartz,et al.  Collagen-shield delivery of gentamicin and vancomycin. , 1988, Archives of ophthalmology.

[43]  Ankita R. Desai,et al.  Pharmacokinetic Studies of Sustained-Release Depot of Dexamethasone in Beagle Dogs , 2016, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[44]  V. Trinkaus-Randall,et al.  Wounding the cornea to learn how it heals. , 2014, Experimental eye research.

[45]  Y. Courtois,et al.  Iontophoresis: from the lab to the bed side. , 2004, Experimental eye research.

[46]  S. P. Srinivas,et al.  Penetration of Fluorescein Across the Rabbit Cornea from the Endothelial Surface , 2012, Pharmaceutical Research.

[47]  Carolyn G. Begley,et al.  The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[48]  Veli-Pekka Ranta,et al.  Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. , 2006, Advanced drug delivery reviews.

[49]  A. Schoubben,et al.  Effect of agitation regimen on the in vitro release of leuprolide from poly(lactic-co-glycolic) acid microparticles. , 2012, Journal of pharmaceutical sciences.

[50]  J. Baum,et al.  Concentration of gentamicin in experimental corneal ulcers. Topical vs subconjunctival therapy. , 1974, Archives of ophthalmology.

[51]  Y. Omidi,et al.  Ocular Drug Delivery; Impact of in vitro Cell Culture Models , 2009, Journal of ophthalmic & vision research.

[52]  Clive G. Wilson,et al.  Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. , 2010, Investigative ophthalmology & visual science.

[53]  M. Dana,et al.  Loss and restoration of immune privilege in eyes with corneal neovascularization. , 1996, Investigative ophthalmology & visual science.

[54]  Sahar Awwad,et al.  The PK-Eye: A Novel In Vitro Ocular Flow Model for Use in Preclinical Drug Development. , 2015, Journal of pharmaceutical sciences.

[55]  Young Kook Kim,et al.  Mathematical modelling of brimonidine absorption via topical delivery of microparticle formulations to the eye , 2016 .

[56]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[57]  S. Ryan,et al.  Pafhogenesis of Laser-Induced Choroidal Subrefinal Neovascularization , 2005 .

[58]  J. Aquavella,et al.  Effect of collagen shields on corneal epithelialization following penetrating keratoplasty. , 1989, Ophthalmic surgery.

[59]  C. Foster,et al.  Epidermal growth factor in alkali-burned corneal epithelial wound healing. , 1987, American journal of ophthalmology.

[60]  N. Shanks,et al.  Are animal models predictive for humans? , 2009, Philosophy, ethics, and humanities in medicine : PEHM.

[61]  M. Andersson,et al.  Extended-term cultures of human T-lymphocytes and the comet assay: a useful combination when testing for genotoxicity in vitro? , 2003, Mutation research.

[62]  A. O'Hagan,et al.  Bayesian calibration of computer models , 2001 .

[63]  D. Azar,et al.  Proangiogenic role of ephrinB1/EphB1 in basic fibroblast growth factor-induced corneal angiogenesis. , 2007, The American journal of pathology.

[64]  H F Edelhauser,et al.  Transscleral drug delivery for posterior segment disease. , 2001, Advanced drug delivery reviews.

[65]  M. Batterbury,et al.  Collagen corneal shields. , 2002, Survey of ophthalmology.

[66]  M. Abelson,et al.  Vehicle-Controlled, Phase 2 Clinical Trial of a Sustained-Release Dexamethasone Intracanalicular Insert in a Chronic Allergen Challenge Model. , 2017, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[67]  A. Cideciyan,et al.  Genetically engineered large animal model for studying cone photoreceptor survival and degeneration in retinitis pigmentosa , 1997, Nature Biotechnology.

[68]  D. Jere,et al.  Evaluation of protein drug stability with vitreous humor in a novel ex-vivo intraocular model. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[69]  H. Bergh,et al.  A new drug-screening procedure for photosensitizing agents used in photodynamic therapy for CNV. , 2001, Investigative ophthalmology & visual science.

[70]  K. Pfarr,et al.  Antibiotic chemotherapy of onchocerciasis: in a bovine model, killing of adult parasites requires a sustained depletion of endosymbiotic bacteria (Wolbachia species). , 2005, The Journal of infectious diseases.

[71]  K. Korzekwa,et al.  On the Nature of Physiologically-Based Pharmacokinetic Models –A Priori or A Posteriori? Mechanistic or Empirical? , 2017, Pharmaceutical Research.

[72]  R. Pfister Chemical Corneal Burns , 1984, International ophthalmology clinics.

[73]  D. Dallatana,et al.  Porcine sclera as a model of human sclera for in vitro transport experiments: histology, SEM, and comparative permeability , 2009, Molecular vision.

[74]  M. Maier,et al.  Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. , 2007, Acta ophthalmologica Scandinavica.